Media stories about Pacific Biosciences of California (NASDAQ:PACB) have trended positive this week, according to Accern. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pacific Biosciences of California earned a news sentiment score of 0.30 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.8421878056828 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the news articles that may have impacted Accern Sentiment’s analysis:

Pacific Biosciences of California (NASDAQ:PACB) traded up 1.30% during midday trading on Monday, hitting $5.44. The company had a trading volume of 254,448 shares. Pacific Biosciences of California has a one year low of $3.08 and a one year high of $9.50. The company’s market cap is $628.82 million. The company’s 50 day moving average is $4.49 and its 200-day moving average is $4.22.

Pacific Biosciences of California (NASDAQ:PACB) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.02). The company had revenue of $20.07 million during the quarter, compared to analyst estimates of $23.34 million. Pacific Biosciences of California had a negative net margin of 89.67% and a negative return on equity of 93.31%. Pacific Biosciences of California’s quarterly revenue was down 3.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.21) EPS. On average, equities analysts predict that Pacific Biosciences of California will post ($0.89) EPS for the current year.

Several equities research analysts recently issued reports on the company. Zacks Investment Research lowered Pacific Biosciences of California from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. BidaskClub raised Pacific Biosciences of California from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 8th. Finally, ValuEngine lowered Pacific Biosciences of California from a “sell” rating to a “strong sell” rating in a research report on Tuesday, June 13th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $10.00.

COPYRIGHT VIOLATION NOTICE: This story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes.

Insider Buying and Selling by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Stock Ratings for Pacific Biosciences of California Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California Inc. and related stocks with our FREE daily email newsletter.